Effect of *Lactobacillus rhamnosus* CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women

Marina Sanchez¹, Christian Darimont², Vicky Drapeau³, Shahram Emady-Azar⁴, Melissa Lepage⁵, Enea Rezzonico², Catherine Ngom-Bru³, Bernard Berger², Lionel Philippe⁴, Corinne Ammon-Zuffrey², Patricia Leone², Genevieve Chevrier⁶, Emmanuelle St-Amand⁶, André Marette⁶, Jean Doré¹ and Angelo Tremblay¹*

¹Department of Kinesiology, Faculty of Medicine, Laval University, Quebec, QC, Canada G1V 0A6
²Nutrition and Health Research Department, Nestlé Research Center, Lausanne, Switzerland
³Department of Physical Education, Faculty of Educational Sciences, Laval University, Quebec, QC, Canada G1V 0A6
⁴Clinical Development Unit, Nestlé Research Center, Lausanne, Switzerland
⁵Analytical Sciences Department, Nestlé Research Center, Lausanne, Switzerland
⁶Research Center of the Institut universitaire de cardiologie et de pneumologie de Québec, Quebec, QC, Canada G1V 4G5

(Submitted 11 July 2013 – Final revision received 1 October 2013 – Accepted 23 October 2013 – First published online 3 December 2013)

Abstract

The present study investigated the impact of a *Lactobacillus rhamnosus* CGMCC1.3724 (LPR) supplementation on weight loss and maintenance in obese men and women over 24 weeks. In a double-blind, placebo-controlled, randomised trial, each subject consumed two capsules per day of either a placebo or a LPR formulation (1.6 × 10⁸ colony-forming units of LPR/capsule with oligofructose and inulin). Each group was submitted to moderate energy restriction for the first 12 weeks followed by 12 weeks of weight maintenance. Body weight and composition were measured at baseline, at week 12 and at week 24. The intention-to-treat analysis showed that after the first 12 weeks and after 24 weeks, mean weight loss was not significantly different between the LPR and placebo groups when all the subjects were considered. However, a significant treatment × sex interaction was observed. The mean weight loss in women in the LPR group was significantly higher than that in women in the placebo group (*P* = 0.02) after the first 12 weeks, whereas it was similar in men in the two groups (*P* = 0.53). Women in the LPR group continued to lose body weight and fat mass during the weight-maintenance period, whereas opposite changes were observed in the placebo group. Changes in body weight and fat mass during the weight-maintenance period were similar in men in both the groups. LPR-induced weight loss in women was associated not only with significant reductions in fat mass and circulating leptin concentrations but also with the relative abundance of bacteria of the Lachnospiraceae family in faeces. The present study shows that the *Lactobacillus rhamnosus* CGMCC1.3724 formulation helps obese women to achieve sustainable weight loss.

Key words: Energy restriction; Probiotics; Body composition; Microbiota

The increase in the prevalence of obesity observed over the last few decades has favoured the numerous investigations that have contributed to better understand the effects of a modern lifestyle on energy balance, body composition and metabolic health. Among the studied potential determinants of obesity, the intestinal microbiota has been proposed to have an impact on energy balance in both animals and humans¹.²

Microbiota may be perceived as an ‘organ’ that contributes to the metabolism and plays a role in energy storage. The human gut microbiota is composed of trillions of bacteria belonging mainly to two bacterial divisions: Firmicutes and Bacteroidetes. Although the diet has an impact on the composition of the gut microbiota³–⁵, these bacteria have been proposed to participate in the development of obesity and diabetes⁶–¹⁰. Animal studies have shown differences in gut microbiota composition associated with obesity¹⁰. Lean mice have a higher relative abundance of Bacteroidetes and a lower abundance of Firmicutes than obese rodents¹⁰. Inoculation of the gut microbiota of obese mice into axenic mice has been shown to induce a significant fat mass gain when compared with that of the gut microbiota of lean animals into mice¹². These data suggest, at least in mice, a potential role for gut microbiota in the development...
of obesity. In human subjects, Million et al.\(^{11}\) have recently demonstrated an association between *Lactobacillus* and weight. They found that certain species of *Lactobacillus* are present in normal-weight individuals, while other species of *Lactobacillus* are present in obese individuals\(^{11}\). Unlike in diabetes\(^{12,13}\), changes in gut microbiota composition associated with obesity or weight loss are less clear in humans. In 2006, Ley et al.\(^{16}\) showed that after consumption of a carbohydrate- or fat-restricted low-energy diet, obese subjects had an increased proportion of Bacteroidetes and a decreased abundance of Firmicutes in their gut, confirming observation made in rodents. However, other studies have reported opposite results or lack of changes in gut microbiota composition\(^{5,14–16}\). These differences might be due to differences in population characteristics and size and methodologies used for analysing microbiota composition.

The potential role of gut microbiota in the development of obesity led several groups to investigate the effects of probiotic consumption on weight management. Probiotics, which are bacteria known to confer health benefits on the host, may modulate the gut microbiota and therefore affect the energy balance and/or metabolism of the host. The administration of specific strains of *Lactobacillus* or *Bifidobacterium* has been shown to prevent weight gain in mouse models of obesity\(^{17}\). Limited evidence exists on the effect of probiotic consumption on weight management in humans. Kadooka et al.\(^{18}\) reported that a supplementation of fermented milk with *Lactobacillus gasseri* SBT2055 for 12 weeks induces significant weight loss (about 1 kg) and a decrease in abdominal visceral and subcutaneous fat mass in overweight men and women under *ad libitum* conditions. Recently, a placebo-controlled, double-blind, cross-over clinical study has shown that the consumption of two yogurts per day supplemented with *Lactobacillus amylovorus* (10\(^9\) colony-forming units (cfu)/yogurt) leads to a decrease in total body fat mass\(^{19}\). Interestingly, Ilmenen et al.\(^{20}\) showed that nutritional counselling combined with probiotic treatment (*Lactobacillus rhamnosus* GG and *Bifidobacterium lactis* Bb12) in pregnant women can reduce the risk of central adiposity at 6 months post-partum.

The aim of the present study was to investigate, for the first time in human subjects, the effects of probiotic consumption during the energy-restriction and weight-maintenance phases. For this purpose, the association between *Lactobacillus rhamnosus* CGMCC1.3724 (LPR) and a low dose of polysaccharides was tested in obese men and women.

**Methods**

Healthy overweight men and women participated in a 24-week randomised, double-blind, placebo-controlled trial that was aimed at facilitating body-weight control by using a two-phase intervention protocol. In phase 1 (weight-loss period), supervised dietary restriction with or without probiotic LPR supplementation was followed over 12 weeks. Phase 2 was a period of weight maintenance with supervision of dietary habits without restriction over 12 weeks during which LPR or placebo supplementation was continued. The present study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Laval Hospital Ethics Committee (CER: 20 449) and by Health Canada (14424). Written informed consent was obtained from all the subjects. The study was registered at ClinicalTrials.gov (NCT01106924).

**Subjects**

Subjects were recruited through different media in the Quebec City area on the basis of the following inclusion and exclusion criteria that were verified during telephone interviews: age between 18 and 55 years; absence of pregnancy, breast-feeding or menopause (determined by the cessation of menstruation); stable body weight (body-weight change < 5 kg for 3 months before screening); BMI between 29 and 41 kg/m\(^2\); without associated co-morbidities (hypertension \(\geq 140/90\) mmHg, obstructive sleep apnoea, type 2 diabetes or CVD, or family history of dyslipidaemia); no abnormal thyroid hormone levels; no immunocompromised conditions or anaemia; no use of vitamin and mineral supplementation within 6 months of screening; no use of medication affecting body weight, energy expenditure, or glucose control or antibiotic treatment for the last 3 months; no smoking, drug or alcohol (>2 drinks/day) problem; consumption of \(\leq 5\) cups of coffee/day (1250 ml/d). Participants with allergy to the ingredients in the study product and placebo or experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain or currently participating or having had participated in another clinical trial during the last 6 months before the beginning of the present study were excluded. A 2-week washout period was included in the intervention programme to eliminate probiotic-containing products in the daily diet before the initiation of treatment. Participants who met these criteria were invited to a pre-selection individual meeting during which body weight and height were measured. They also received more information about the protocol and explanations about the dietary and physical activity records that had to be completed at home. Baseline characteristics of the participants are given in Table 1. The first step of screening allowed the recruitment of 153 participants. The participants were aware of the study objectives, but they were blinded regarding the supplementation (LPR or placebo) that was assigned according to the computerised randomisation system. After randomisation, blood samples were analysed and twenty-eight subjects were excluded because of dyslipidaemia (plasma TAG levels \(>200\) mmol/l).}

Fig. 1 shows the distribution of subjects within each study group. The LPR formulation and the placebo were administered orally. All the participants had to ingest one capsule 30 min before breakfast and one capsule 30 min before dinner. The subjects were tested at baseline, at week 12 (after the weight-loss phase) and at week 24 (after the weight-maintenance phase) of the programme. The participants arrived at the laboratory at about 08.00 hours, after a 12 h overnight fast, during each testing session, and they had to abstain from physical exercise for 48 h and from alcohol intake for 24 h before the testing session. For women, testing sessions were held during the first 10 d of their menstrual cycle.
<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Placebo</th>
<th>Male</th>
<th>Placebo</th>
<th>Male</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean</strong></td>
<td></td>
<td></td>
<td><strong>Mean</strong></td>
<td></td>
<td><strong>Mean</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SE</strong></td>
<td></td>
<td></td>
<td><strong>SE</strong></td>
<td></td>
<td><strong>SE</strong></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>35.0 10.0</td>
<td>37.0 10.0</td>
<td>37.0 10.0</td>
<td>30.0 10.0</td>
<td>34.0 10.0</td>
<td>36.0 10.0</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>95.1 13.9</td>
<td>94.0 14.9</td>
<td>103.1 13.0</td>
<td>103.1 13.0</td>
<td>99.3 9.6</td>
<td>99.7 8.9</td>
</tr>
<tr>
<td>BMI (kg/m^2)</td>
<td>33.8 3.3</td>
<td>33.3 3.2</td>
<td>34.0 2.8</td>
<td>33.5 3.3</td>
<td>33.6 3.6</td>
<td>33.2 3.2</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>38.5 8.66</td>
<td>37.4 8.88</td>
<td>34.0 8.26</td>
<td>32.8 9.12</td>
<td>40.8 8.19</td>
<td>40.21 7.55</td>
</tr>
<tr>
<td>Fat mass (kg)</td>
<td>40.82 7.68</td>
<td>40.08 8.22</td>
<td>33.11 4.94</td>
<td>31.41 5.26</td>
<td>45.57 4.57</td>
<td>45.41 4.10</td>
</tr>
<tr>
<td>Fat mass (% of body weight)</td>
<td>56.3 5.4</td>
<td>55.94 8.45</td>
<td>63.44 4.82</td>
<td>64.96 5.14</td>
<td>50.33 4.62</td>
<td>50.39 4.21</td>
</tr>
<tr>
<td>Mean daily energy intake (kcal)</td>
<td>2510 676 2362 611</td>
<td>2998 550 2752 479</td>
<td>2265 636 2122 562</td>
<td>9477 2661 8878 2351</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean daily energy intake (kJ)</td>
<td>10502 2828 9883 2556</td>
<td>12125 2301 11514 2004</td>
<td>1158 8 1190 9</td>
<td>9477 2661 8878 2351</td>
<td></td>
<td></td>
</tr>
<tr>
<td>REE (kcal/min)</td>
<td>1.22 0.21</td>
<td>1.18 0.20</td>
<td>1.38 0.16</td>
<td>1.34 0.18</td>
<td>1.12 0.16</td>
<td>1.08 0.13</td>
</tr>
<tr>
<td>REE (kJ/min)</td>
<td>5.10 0.88</td>
<td>4.94 0.84</td>
<td>5.77 0.67</td>
<td>5.61 0.75</td>
<td>4.68 0.67</td>
<td>4.52 0.54</td>
</tr>
<tr>
<td>RQ</td>
<td>0.85 0.09</td>
<td>0.86 0.08</td>
<td>0.88 0.10</td>
<td>0.87 0.08</td>
<td>0.83 0.08</td>
<td>0.85 0.07</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>65.6 6.0</td>
<td>66.0 6.1</td>
<td>65.4 6.4</td>
<td>65.6 5.8</td>
<td>65.6 5.8</td>
<td>66.3 6.4</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>118.5 10.5</td>
<td>119.0 9.7</td>
<td>112.3 11.8</td>
<td>119.6 10.4</td>
<td>115.8 8.4</td>
<td>119.0 9.8</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>76.4 7.9</td>
<td>76.8 7.7</td>
<td>77.7 8.4</td>
<td>77.7 8.2</td>
<td>75.1 7.4</td>
<td>76.6 7.6</td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>4.9 1.0</td>
<td>5.1 0.8</td>
<td>5.3 0.6</td>
<td>5.5 0.9</td>
<td>4.6 1.2</td>
<td>4.9 0.6</td>
</tr>
<tr>
<td>Fasting insulin (pmol/l)</td>
<td>63.5 29.5</td>
<td>63.1 34.6</td>
<td>69.0 27.9</td>
<td>68.7 39.0</td>
<td>60.5 29.8</td>
<td>59.7 32.0</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.6 0.9</td>
<td>4.3 0.8</td>
<td>4.6 0.9</td>
<td>4.1 0.9</td>
<td>4.7 0.8</td>
<td>4.4 0.8</td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td>1.1 0.4</td>
<td>1.1 0.4</td>
<td>1.3 0.4</td>
<td>1.1 0.4</td>
<td>1.1 0.4</td>
<td>1.0 0.4</td>
</tr>
<tr>
<td>LDL (mmol/l)</td>
<td>2.8 0.8</td>
<td>2.5 0.7</td>
<td>2.8 0.8</td>
<td>2.5 0.8</td>
<td>2.7 0.8</td>
<td>2.5 0.7</td>
</tr>
<tr>
<td>HDL (mmol/l)</td>
<td>1.3 0.4</td>
<td>1.3 0.3</td>
<td>1.1 0.2</td>
<td>1.1 0.2</td>
<td>1.5 0.4</td>
<td>1.4 0.3</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>36.5 24.2</td>
<td>36.0 25.2</td>
<td>17.9 12.5</td>
<td>16.5 16.7</td>
<td>48.5 22.6</td>
<td>47.9 21.7</td>
</tr>
<tr>
<td>Adiponectin (ng/ml)</td>
<td>8912.7 4243.2</td>
<td>8224.5 3582.7</td>
<td>7575.0 3164.5</td>
<td>7141.2 3079.6</td>
<td>9933.5 4651.9</td>
<td>8824.9 3779.5</td>
</tr>
<tr>
<td>Glyceral (mmol/l)</td>
<td>0.06 0.03</td>
<td>0.06 0.03</td>
<td>0.03 0.01</td>
<td>0.03 0.01</td>
<td>0.07 0.03</td>
<td>0.08 0.03</td>
</tr>
<tr>
<td>NEFA (mmol/l)</td>
<td>0.46 0.14</td>
<td>0.44 0.17</td>
<td>0.36 0.09</td>
<td>0.36 0.17</td>
<td>0.52 0.14</td>
<td>0.50 0.16</td>
</tr>
<tr>
<td>β-Hydroxybutyrate (μmol/l)</td>
<td>57.0 53.6</td>
<td>51.4 53.6</td>
<td>44.3 41.0</td>
<td>57.5 73.9</td>
<td>64.1 59.2</td>
<td>47.1 36.2</td>
</tr>
<tr>
<td>LBP (μg/ml)</td>
<td>14.3 7.1</td>
<td>15.7 9.6</td>
<td>12.7 4.7</td>
<td>16.0 12.6</td>
<td>15.5 8.2</td>
<td>15.4 7.4</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>4.6 5.2</td>
<td>5.4 6.9</td>
<td>3.9 5.0</td>
<td>3.0 4.1</td>
<td>5.1 5.4</td>
<td>6.8 7.9</td>
</tr>
</tbody>
</table>

LPR, *Lactobacillus rhamnosus* CGMCC1.3724; REE, resting energy expenditure; RQ, respiratory quotient; HR, heart rate; bpm, beats/min; SBP, systolic blood pressure; DBP, diastolic blood pressure; LBP, lipopolysaccharide-binding protein; CRP, C-reactive protein.
Treatment
The probiotic capsules contained a formulation consisting of 10 mg of a LPR powder providing $1.62 \times 10^8$ cfu, 300 mg of a mix of oligofructose and inulin (70:30, v/v) and 3 mg of magnesium stearate. The placebo capsules were of the same colour and size as the LPR capsules and contained 250 mg of maltodextrin and 3 mg of magnesium stearate. The subjects consumed two capsules per d corresponding to an average of $3.24 \times 10^8$ cfu/d in the probiotic group. When combined with prebiotics or other probiotics, LPR has been shown to promote healthy growth in toddlers and to reduce risks of eczema in infants.\(^{(21,22)}\)

Daily energy intake and physical activity measurements
A standardised 3 d dietary record\(^{(23)}\) was obtained from each participant. This record was completed at home after the participants had received detailed explanations from a dietitian. A computerised version of the Canadian Nutrition File (version 2005) was used to determine the macro- and micronutrient content of foods as well as total daily energy intake\(^{(24)}\). This measurement was repeated at the end of the weight-loss period (phase 1) and the weight-maintenance period (phase 2). A 3 d physical activity record was also completed at home on the same days the dietary record was completed. In addition, the participants completed a 24 h dietary recall with the assistance of the dietitian every 2 weeks during phase 1 and every month during phase 2. These records or recalls provided reference information of each participant to the dietitian to standardise the counselling and related guidelines over the two phases of the intervention programme.

Energy-restricted diet
As has been indicated above, each participant received a personalised diet plan targeting 2092 kJ/d (500 kcal/d) energy restriction for the first 12 weeks of the programme. During phase 2, each participant received a personalised diet plan without energy restriction. The energy content of the diets was determined by a dietitian from the daily energy requirement of each participant. The daily energy requirement was estimated using resting energy expenditure and multiplying it by an activity factor based on the physical activity record. Resting energy expenditure was determined after a 12 h overnight fast in subjects having had rested for at least 15 min in a standardised supine position. Resting energy expenditure was measured at baseline and was reassessed after the weight-loss and weight-maintenance periods using indirect calorimetry. Specifically, expired air was collected through a mouthpiece.

Fig. 1. Flow chart of the study protocol. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn).
with the nose being clipped. The concentrations of oxygen (electrochemical oxygen sensor) and CO₂ (non-dispersive IR analysis) were determined using an Uras 10 E device (Hartmann & Braun), whereas pulmonary ventilation was assessed using a K520 flow transducer and a Spirometric module S-430A measurement system (KL Engineering). The Weir formula was used to determine the energy equivalent of O₂ volume. The food plan was based on an exchange food group list adapted from the Meal Planning for People with Diabetes.

Apart from the supplement, both the groups were limited to consume a maximum of four servings of products supplemented with probiotics per week. Each participant met his or her assigned dietitian every 2 weeks during phase 1 and every 4 weeks during phase 2. The participants’ compliance to the diet plan was measured by comparing the prescribed diet composition (total daily energy intake and macronutrient composition) with the actual diet composition measured every 2 weeks by a 24 h dietary recall. The participants’ compliance to the supplementation was measured using the compliance journal every 2 and 4 weeks during the weight-loss period and the weight-maintenance period, respectively. Participants who discontinued taking the treatment (LPR or placebo) for three consecutive days were excluded.

**Anthropometric parameter and body composition measurements**

Body weight, height (light clothes and without shoes) and waist circumference (directly on the skin) were assessed at baseline, every 2 weeks during phase 1 as well as at the end of this phase, and every 4 weeks during phase 2 and at the end of this phase, except for height. BMI was calculated as body weight divided by height squared (kg/m²). During each testing session, heart rate, systolic blood pressure and diastolic blood pressure were assessed in a supine position (directly on the skin) were assessed at 30 and 120 min by plating and growing Lactobacilli for 48 h under anaerobic conditions on de Man, Rogosa and Sharpe (MRS) agar medium plates (methods adapted from Sutter et al.). Cfu were counted and are reported as cfu/ml of solution.

**Biochemical analyses**

Blood samples were collected into EDTA-containing tubes (Miles Pharmaceuticals) and heparin-containing tubes at about 08.00 hours following an overnight fast for at least 12 h. These samples were used for the determination of plasma concentrations of glucose, insulin, leptin, lipids, lipoproteins and inflammatory indicators, which were measured at three time points (baseline, week 12 and week 24). The concentration of glucose was measured enzymatically, that of insulin was determined by an electrochemiluminescence immunoassay, that of leptin was determined using an ELISA array (Human C-Reactive Protein ELISA Kit; EDM Millipore). The plasma concentration of adiponectin was determined using an enzymatic assay (Wako). The serum concentration of LBP was assayed using an ELISA kit (Hycult Biotech). The plasma concentration of adiponectin was determined using an ELISA array obtained from Millipore.

**In vitro gastrointestinal Lactobacillus rhamnosus CGMCC1.3724 survival assay**

LPR (6·10⁸ cfu) was incubated at 37°C in 1 ml of gastric (0·3% porcine pepsin + NaCl 0·55 adjusted at pH 2·5) or duodenal (0·2 M-phosphate buffer at pH 6·8 + 0·49% porcine bile + 0·24% porcine pancreatin) simulated juices in the presence or not in the presence of 0·01, 0·1 or 1% of oligofructose/inulin (70:30, v/v; Benecol). After 30 min of incubation in the gastric juice, 100 µl of the mix were transferred into the duodenal juice for 90 min. LPR viability was assessed at 30 and 120 min by plating and growing Lactobacilli for 48 h under anaerobic conditions on de Man, Rogosa and Sharpe (MRS) agar medium plates (methods adapted from Sutter et al.). Cfu were counted and are reported as cfu/ml of solution.

**Sequence-based microbiota analysis**

Faecal samples were collected from the placebo-treated and probiotic-treated subjects at baseline, end of phase 1, and end of phase 2, and samples were stored at −80°C until analysis. Frozen faecal samples were reduced to a powder using a cryoPREP device (Covaris), and total DNA was extracted using the QIAamp DNA Stool Mini Kit (QIAGEN), following the manufacturer’s instructions, except for the addition of a series of mechanical disruption steps (11×45 s) using a FastPrep apparatus and Lysing Matrix B tubes (MP Biochemicals). PCR amplification was carried out using two sets of primers targeting the hypervariable regions (V) 1–3 (V123) and 4–6 (V456) of the 16S ribosomal RNA gene. For the amplification of the V123 region, a mixture of forward primers targeting the hypervariable regions (V) 1–3 (V123) and 4–6 (V456) of the 16S ribosomal RNA gene. For the amplification of the V123 region, a mixture of forward primers was combined to ensure optimal coverage of bacterial phylogenetic diversity, as described previously. The primers were designed according to Hamady et al.:

- V123 forward primer 1, 5'-CTATGGCGCTTGGGAGGCGCTAGTCAGTCAGTGGTAGTTGATCGAGCTAGTGGAGTCAGATCTGCGTCGAGGTAGTCTGGCTCGAG-3';
- V123 forward primer 2, 5'-CTATGGCGCTTGGGAGGCGCTAGTCAGTCAGTGGTAGTTGATCGAGCTAGTGGAGTCAGATCTGCGTCGAGGTAGTCTGGCTCGAG-3';
- V123 forward primer 3, 5'-CTATGGCGCTTGGGAGGCGCTAGTCAGTCAGTGGTAGTTGATCGAGCTAGTGGAGTCAGATCTGCGTCGAGGTAGTCTGGCTCGAG-3';
- V123 forward primer 4, 5'-CTATGGCGCTTGGGAGGCGCTAGTCAGTCAGTGGTAGTTGATCGAGCTAGTGGAGTCAGATCTGCGTCGAGGTAGTCTGGCTCGAG-3';
- V123 reverse primer, 3'-AGAAATTAGTCATCGTTAGTCAGTGGAGTCAGATCTGGCTCGAG-3'.
5'-CGTATCGCTCCCTGCGCCCATCAAGNNNNNNNGTTACGCGGGGCTGCTGGCGAC-3'; V456 forward primer, 5'-CT-ATGCGGCTTGGCCAGGCGGCCTACAGCRRCCAGGACGTCGAC-AGCGAC-3', and V456 reverse primer, CGTATCGCTCCCTGCGCCCATCAAGNNNNNNNAGCCACAGCCCGCGTGTA-3' (where the adapter sequences for Roche 454 FLX Titanium sequencing are italicised, the linkers are underlined, NNNNNNNN designates the sample-specific eight-base barcodes used to tag each PCR product, and bold sequences correspond to broadly conserved 16S ribosomal RNA gene regions). V123 forward primers 1, 2, 3 and 4 were combined in 4:1:1:1 ratios.

Amplifications were performed in 50 μl volumes with 2 μl of DNA extract, 50 μM of deoxyribonucleotide triphosphate (dNTP), 200 nM of forward primers (mix of forward primers for the V123 region), 200 nM of reverse primers, 1 X Expand High Fidelity Reaction Buffer and 5 U/100 μl of Expand High Fidelity™ enzyme blend (Roche Applied Science). PCR conditions were as follows: 94°C for 2 min followed by twenty-five cycles of 94°C for 30 s, 49°C for 30 s, and 72°C for 1 min, ending with a final step of 72°C for 7 min. After purification, pooling in equimolar amounts, the PCR products were sequenced using the 454 FLX Titanium technology (Microsynth AG). Raw data were analysed using the QIIME software package (35) with default parameters, except that no barcode correction was allowed, and reverse primers were removed when present. The chimeras were detected and removed using ChimeraSlayer based on reference alignment from GreenGenes (as provided in QIIME 1.2) and default parameters. Samples described by less than 200 sequencing reads were excluded from the analysis. Quality-filtered sequencing reads were analysed using the Uclust method at a similarity threshold of 97% identity for operational taxonomic unit clustering. The assignment of operational taxonomic unit into Bergey’s bacterial taxonomy was done using the Ribosomal Database Project (RDP) Classifier with a confidence value threshold of 60%.

Quantification of faecal Lactobacillus rhamnosus CGMCC1.3724

The quantification of Lactobacillus rhamnosus CGMCC1.3724 was carried out by quantitative PCR using faecal DNA as described previously (36). Dilutions of genomic DNA of L. rhamnosus CGMCC1.3724 were used to prepare a calibration curve (0-0 pg–20 ng). Measured DNA quantities were converted into number of genome equivalents/g of faeces based on the molecular weight of the L. rhamnosus CGMCC1.3724 genome (3-278 fg/ genome). The limit of quantification (1.26 × 105 genome equivalents/g of faeces) was set to 10-fold of the measured quantitative PCR detection limit, to take into account potential contamination during sample analysis.

Statistical analysis (clinical outcomes)

The outcome measures were analysed using ANCOVA considering changes over time in a mixed model setting treatment and sex as independent variables while correcting for baseline values in the model. The change in fat mass over time was also considered as an independent variable for the ANCOVA pertaining to changes in plasma leptin concentrations over time. Furthermore, the effect of treatment × sex interaction in the model was examined. The analyses were carried out on the intention-to-treat population utilising SAS version 9.2 (SAS Institute). Statistical significance level was set at 5%, and no correction of significance level was applied to adjust for multiple testing. Sample size calculation was implemented using the statistical and power analysis software NCSS. The calculations were primarily driven by the intention to show superiority in mean body-weight reduction at a significance level of 5% and with a statistical power of 80%. The initial calculations suggested that the testing of 104 subjects (fifty-two per group) was required to get adequate statistical power. In addition, since a dropout rate of about 12% subjects was anticipated, we planned to recruit 120 obese subjects (sixty per treatment group). The sample of 104 subjects estimated above was also expected to provide adequate power to address the important secondary objective aiming at the detection of a between-treatment difference in body-weight change of 1.5 kg or more during the weight-maintenance phase of the programme.

Statistical analysis (microbiota composition)

Statistical analysis of differences between the groups with regard to the relative abundance of individual taxonomic groups was assessed using two-sided Wilcoxon signed-rank tests. This analysis is consistent with the analysis on the clinical outcomes, but slightly refined to take the microbiota data specificities into account. First, the analysis was carried out during visits (while checking the baseline levels), since the clinical relevance of assessing the difference between two relative abundance values is very low. Second, a non-parametric approach was preferred due to the non-normal distribution of the microbiota data. Moreover, the statistical analysis was carried out by sex, based on the information gathered from the clinical outcomes. No correction of significance level was applied to adjust for multiple testing. However, since the analysis was carried out on two 16S ribosomal RNA gene regions separately, only taxa showing consistent differences in both the regions, with a significance level of 5% and median relative abundance greater than or equal to 0.1% in at least one group, were examined.

Results

Improvement of Lactobacillus rhamnosus CGMCC1.3724 viability

Metabolisable sugars have been reported to improve the survival of Lactobacillus rhamnosus strain LGG in gastrointestinal conditions through ATP production (37). The survival of LPR in simulated gastrointestinal tract conditions was assessed in vitro by incubating the probiotic in a medium mimicking the upper gastrointestinal tract conditions (stomach and duodenum) containing or not containing a mixture of oligosaccharides and polysaccharides (fructo-oligosaccharides–inulin 70:30). The viability of LPR was only slightly affected under the simulated gastric conditions, whereas under duodenal conditions...
conditions bacterial counts were dramatically decreased ($-5.00$ (SE 0.06) log (cfu/ml); Fig. 2). Supplementation of 0.1% of a mixture of oligosaccharides and polysaccharides significantly improved the resistance of LPR to duodenal conditions ($-1.76$ (SE 0.14) log (cfu/ml); Fig. 2). Based on these results and the assumption that probiotic viability is required for the efficacy of LPR, 300 mg of the oligosaccharide and polysaccharide mixture were added to each ingredient capsule to improve probiotic gastrointestinal tract survival and support functionality. This dose of oligosaccharides and polysaccharides corresponds to a dose that is 100-fold higher than the maximal dose tested in vitro in order to ensure optimal survival during capsule filling and gastrointestinal transit.

**Intervention trial: effects on body weight and body composition**

Variations in body weight and composition are summarised in Table 2. The intention-to-treat analysis showed that treatment with the LPR formulation did not significantly change weight loss during the energy-restriction period (week 12, phase 1) and after the weight-maintenance period (week 24, phase 2) in the population regrouping male and female subjects. Fat mass was also not significantly modified by the LPR formulation at week 12, but it tended to be decreased by the treatment at week 24 (changes in fat mass compared with those observed with the placebo treatment: $-1.42$ (SE 0.79) kg; $P=0.07$; values are corrected for the baseline values). A significant treatment × sex interaction effect was observed for some variables. Specifically, during phase 1, reductions in body weight and fat mass were more pronounced in the LPR-treated women than in the placebo-treated women (changes in body weight compared with those observed with the placebo treatment: $-2.54$ (SE 1.01) kg; $P=0.01$; changes in fat mass compared with those observed with the placebo treatment: $-2.6$ (SE 1.1) kg; $P=0.02$; changes in fat mass compared with those observed with the placebo treatment: $-2.9$ (SE 0.8) kg; $P=0.01$; values are corrected for the baseline values). The body weight and fat mass of men were not affected by the treatment during the two phases of the programme.

**Energy balance and physiological parameters**

Table 2 also summarises the values of reported daily energy intake in each group of subjects at baseline and at the end of the two phases of the programme (weeks 12 and 24). As expected, the reported energy intake was reduced at week 12, which is compatible with the dietary restriction that was planned at the beginning of the intervention. In each group, this reduced energy intake was maintained at week 24, and no difference between the placebo and LPR groups and between the sexes was observed during the two phases. However, in spite of a lack of significant differences, energy intake seemed to be consistently lower in the LPR-treated women in both phase 1 and phase 2, when compared with that in women in the placebo group (Table 2).

Variations in other physiological parameters are summarised in Table 2. The LPR treatment did not exert any significant effect on resting energy expenditure, respiratory quotient, heart rate and diastolic blood pressure, during both phase 1 and phase 2.

**Metabolic and inflammatory plasma markers**

There was no significant treatment and treatment × sex interaction effect on the metabolic and inflammatory plasma markers during the programme, except for plasma leptin (Table 3). Indeed, at week 24, a more pronounced decrease in fasting leptin concentrations was found in the population, including males and females in the LPR group compared with their placebo counterparts (changes compared with those observed with the placebo treatment: $-5.9$ (SE 2.3) ng/ml; $P=0.01$; values are corrected for the baseline values). This effect of LPR on plasma leptin concentrations of the population regrouping both the sexes was mainly driven by an important effect in females (changes compared with those observed with the placebo treatment: $-11.0$ (SE 2.9) ng/ml; $P=0.004$; values are corrected for the baseline values). These differences remained significant when the values were corrected for the loss of fat mass between baseline and week 24, suggesting that LPR decreased plasma leptin concentrations independently of fat mass reduction.

**Microbiota analyses**

The sequencing of 16S ribosomal RNA gene libraries in stool samples collected at baseline, at week 12 and at week 24 generated, on average, 925 and 823 quality-filtered reads/sample for the V123 and V456 regions, respectively. The following
number of samples per group and per time point fulfilled the quality criteria for consideration of sequencing results: fifty-two, fifty-four samples from the placebo group at baseline, week 12 and week 24, respectively; fifty-two, fifty and forty-two samples from the LPR group at baseline, week 12 and week 24, respectively. Diversity rarefaction curves reached a plateau, suggesting that the current sequencing effort captured most of the phylogenetic diversity within the samples (data not shown). Phylogenetic diversity was not distinguishable between the sexes (at baseline) and groups (at all time points; data not shown). As expected, the quantification of overall microbiota similarity between the samples, measured based on weighted UniFrac distances, revealed a higher similarity between the samples collected from the same subjects at different time points than between the samples collected from different subjects (Fig. 3). The relative abundance of individual bacterial taxonomic groups was analysed at phylum, class, order, family and genus levels, and it is reported as median hereafter. At baseline and at weeks 12 and 24, no significant difference was detected between the groups (LPR v. placebo). Considering the sex \( \times \) treatment interaction observed for the anthropometric parameters (described above), we stratified the groups by sex. At baseline, a significant difference was detected between males and females with regard to the relative abundance of bacteria of the Prevotellaceae family. However, this taxonomic group

---

**Table 2. Changes in body weight, body composition and physiological variables during the intervention programme (Mean values with their standard errors)**

<table>
<thead>
<tr>
<th></th>
<th>LPR formulation</th>
<th>Placebo</th>
<th>LPR formulation</th>
<th>Placebo</th>
<th>LPR formulation</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>∆Week 12-baseline (n)</td>
<td>52</td>
<td>53</td>
<td>23</td>
<td>22</td>
<td>29</td>
<td>31</td>
</tr>
<tr>
<td>∆Week 12-baseline (kg)</td>
<td>45</td>
<td>48</td>
<td>19</td>
<td>20</td>
<td>26</td>
<td>28</td>
</tr>
<tr>
<td>∆Body weight (kg)</td>
<td>−4.2</td>
<td>3.2</td>
<td>−3.4</td>
<td>2.9</td>
<td>−4.0</td>
<td>3.4</td>
</tr>
<tr>
<td>∆Week 24-baseline (kg)</td>
<td>−5.3</td>
<td>4.3</td>
<td>−3.9</td>
<td>4.2</td>
<td>−5.4</td>
<td>4.8</td>
</tr>
<tr>
<td>∆Fat mass (kg)</td>
<td>−3.51</td>
<td>2.39</td>
<td>−2.76</td>
<td>2.83</td>
<td>−3.02</td>
<td>2.70</td>
</tr>
<tr>
<td>∆Week 24-baseline (%)</td>
<td>−4.59</td>
<td>3.80</td>
<td>−3.10</td>
<td>3.98</td>
<td>−4.30</td>
<td>4.14</td>
</tr>
<tr>
<td>∆Fat mass (%)</td>
<td>−2.16</td>
<td>1.94</td>
<td>−1.82</td>
<td>2.40</td>
<td>−2.07</td>
<td>2.06</td>
</tr>
<tr>
<td>∆Fat-free mass (kg)</td>
<td>−3.13</td>
<td>3.41</td>
<td>−2.13</td>
<td>3.11</td>
<td>−2.88</td>
<td>3.24</td>
</tr>
<tr>
<td>∆Fat-free mass (%)</td>
<td>−0.56</td>
<td>1.80</td>
<td>−0.49</td>
<td>1.99</td>
<td>−0.65</td>
<td>1.81</td>
</tr>
<tr>
<td>∆Week 12-baseline (%)</td>
<td>−0.56</td>
<td>1.52</td>
<td>−0.31</td>
<td>1.79</td>
<td>−0.82</td>
<td>1.56</td>
</tr>
<tr>
<td>∆Week 24-baseline (%)</td>
<td>2.15</td>
<td>2.00</td>
<td>1.87</td>
<td>2.49</td>
<td>2.10</td>
<td>1.99</td>
</tr>
<tr>
<td>∆Fat-free mass (%)</td>
<td>3.05</td>
<td>3.53</td>
<td>2.38</td>
<td>2.79</td>
<td>2.92</td>
<td>3.40</td>
</tr>
<tr>
<td>∆Fat-free mass (%)</td>
<td>343</td>
<td>440</td>
<td>−312</td>
<td>454</td>
<td>341</td>
<td>432</td>
</tr>
<tr>
<td>∆Male daily energy intake (kcal)</td>
<td>429</td>
<td>479</td>
<td>402</td>
<td>433</td>
<td>405</td>
<td>454</td>
</tr>
<tr>
<td>∆Male daily energy intake (kJ)</td>
<td>343</td>
<td>440</td>
<td>−312</td>
<td>454</td>
<td>341</td>
<td>432</td>
</tr>
<tr>
<td>∆REE (kcal/min)</td>
<td>−1795</td>
<td>2000</td>
<td>−1682</td>
<td>1812</td>
<td>−1695</td>
<td>1900</td>
</tr>
<tr>
<td>∆REE (kJ/min)</td>
<td>−1435</td>
<td>1841</td>
<td>−1305</td>
<td>1900</td>
<td>−1427</td>
<td>1807</td>
</tr>
<tr>
<td>∆REE (kJ/min)</td>
<td>−0.06</td>
<td>0.10</td>
<td>−0.04</td>
<td>0.10</td>
<td>−0.05</td>
<td>0.10</td>
</tr>
<tr>
<td>∆REE (kJ/min)</td>
<td>−0.06</td>
<td>0.11</td>
<td>−0.02</td>
<td>0.11</td>
<td>−0.02</td>
<td>0.13</td>
</tr>
<tr>
<td>∆RRQ</td>
<td>−0.01</td>
<td>0.07</td>
<td>−0.01</td>
<td>0.08</td>
<td>−0.01</td>
<td>0.07</td>
</tr>
<tr>
<td>∆HR (bpm)</td>
<td>−0.00</td>
<td>0.09</td>
<td>−0.01</td>
<td>0.08</td>
<td>−0.02</td>
<td>0.10</td>
</tr>
<tr>
<td>∆Week 12-baseline</td>
<td>−1.5</td>
<td>6.9</td>
<td>−1.7</td>
<td>6.6</td>
<td>−1.8</td>
<td>7.9</td>
</tr>
<tr>
<td>∆Week 24-baseline</td>
<td>−3.0</td>
<td>6.0</td>
<td>−2.9</td>
<td>7.3</td>
<td>−2.1</td>
<td>6.9</td>
</tr>
<tr>
<td>∆SBP (mmHg)</td>
<td>−2.7</td>
<td>8.1</td>
<td>−5.0</td>
<td>10.3</td>
<td>−4.0</td>
<td>9.5</td>
</tr>
<tr>
<td>∆DBP (mmHg)</td>
<td>−1.2*</td>
<td>9.9</td>
<td>−6.1</td>
<td>9.4</td>
<td>−0.7</td>
<td>11.2</td>
</tr>
</tbody>
</table>
| LPR, Lactobacillus rhamnosus CGMCC1.3724; REE, resting energy expenditure; RRQ, respiratory quotient; HR, heart rate; bpm, beats/min; SBP, systolic blood pressure; DBP, diastolic blood pressure. * Mean values were significantly different from those of the placebo group (P<0.05).
Table 3. Changes in metabolic and inflammatory markers during the intervention programme
(Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>LPR Placebo</th>
<th></th>
<th>LPR Placebo</th>
<th></th>
<th>LPR Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SE</td>
<td>Mean</td>
<td>SE</td>
<td>Mean</td>
</tr>
<tr>
<td>ΔWeek 12-baseline (n)</td>
<td>52</td>
<td>53</td>
<td>23</td>
<td>22</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>45</td>
<td>48</td>
<td>19</td>
<td>20</td>
<td>26</td>
</tr>
<tr>
<td>ΔWeek 24-baseline (n)</td>
<td>0.2</td>
<td>0.7</td>
<td>0.0</td>
<td>0.3</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>0.2</td>
<td>0.8</td>
<td>0.1</td>
<td>0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>ΔFasting glucose (mmol/l)</td>
<td>0.0</td>
<td>0.3</td>
<td>0.0</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>−0.1</td>
<td>0.4</td>
<td>−0.2</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>ΔFasting insulin (pmol/l)</td>
<td>0.0</td>
<td>0.3</td>
<td>0.0</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>−2.8</td>
<td>17.7</td>
<td>−20.9</td>
<td>229.4</td>
<td>−15.2</td>
</tr>
<tr>
<td>ΔTotal cholesterol (mmol/l)</td>
<td>0.0</td>
<td>0.3</td>
<td>0.0</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>−0.2</td>
<td>0.4</td>
<td>−0.2</td>
<td>0.4</td>
<td>−0.2</td>
</tr>
<tr>
<td>ΔTAG (mmol/l)</td>
<td>−0.1</td>
<td>0.3</td>
<td>−0.1</td>
<td>0.4</td>
<td>−0.1</td>
</tr>
<tr>
<td></td>
<td>−0.0</td>
<td>0.3</td>
<td>−0.1</td>
<td>0.3</td>
<td>−0.1</td>
</tr>
<tr>
<td>ΔLDL (mmol/l)</td>
<td>−0.2</td>
<td>0.5</td>
<td>−0.1</td>
<td>0.4</td>
<td>−0.2</td>
</tr>
<tr>
<td></td>
<td>−0.2</td>
<td>0.4</td>
<td>−0.1</td>
<td>0.4</td>
<td>−0.2</td>
</tr>
<tr>
<td>ΔHDL (mmol/l)</td>
<td>0.0</td>
<td>0.2</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>0.0</td>
<td>0.2</td>
<td>0.1</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>ΔLeptin (ng/ml)</td>
<td>−0.7</td>
<td>8.0</td>
<td>−4.8</td>
<td>11.7</td>
<td>−10.2</td>
</tr>
<tr>
<td></td>
<td>−8.1*</td>
<td>10.4</td>
<td>−8.0</td>
<td>12.1</td>
<td>−11.3*</td>
</tr>
<tr>
<td>ΔWeek 12-baseline (n)</td>
<td>149-8</td>
<td>1641-6</td>
<td>15-2</td>
<td>1698-4</td>
<td>25-3</td>
</tr>
<tr>
<td></td>
<td>439</td>
<td>1669-7</td>
<td>1073-6</td>
<td>1974-7</td>
<td>1574-4</td>
</tr>
<tr>
<td>ΔGlycerol (mmol/l)</td>
<td>0.0</td>
<td>0.2</td>
<td>−0.1</td>
<td>0.3</td>
<td>−0.0</td>
</tr>
<tr>
<td></td>
<td>−0.0</td>
<td>0.2</td>
<td>−0.0</td>
<td>0.1</td>
<td>−0.0</td>
</tr>
<tr>
<td>ΔNEFA (mmol/l)</td>
<td>−0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.1</td>
<td>−0.0</td>
</tr>
<tr>
<td></td>
<td>−0.0</td>
<td>0.1</td>
<td>0.0</td>
<td>0.1</td>
<td>−0.0</td>
</tr>
<tr>
<td>Δβ-Hydroxybutyrate (µmol/l)</td>
<td>0.0</td>
<td>0.2</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>16.9</td>
<td>63.9</td>
<td>14.1</td>
<td>89.6</td>
<td>9.5</td>
</tr>
<tr>
<td>ΔLBP (µg/ml)</td>
<td>0.1</td>
<td>3.7</td>
<td>−0.5</td>
<td>4.2</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>3.6</td>
<td>0.2</td>
<td>5.1</td>
<td>0.1</td>
</tr>
<tr>
<td>ΔCRP (mg/l)</td>
<td>0.1</td>
<td>4.4</td>
<td>−1.2</td>
<td>5.4</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>4.3</td>
<td>−0.5</td>
<td>5.7</td>
<td>0.8</td>
</tr>
</tbody>
</table>

LPR, Lactobacillus rhamnosus CGMCC1.3724; LBP, lipopolysaccharide-binding protein; CRP, C-reactive protein.

*Mean values were significantly different from those of the placebo group (P<0.01).
represented only a tiny fraction of the global microbiota (0% in males vs. 0.1% in females; with \( P = 0.03 \) and \( P = 0.05 \) for V123 and V456, respectively). In males, the LPR treatment did not affect the microbiota composition at any time point, except for a low-abundance unclassified taxonomic group belonging to the Firmicutes phylum that was quantified at week 12 at a slightly higher relative abundance in the placebo group than in the LPR group (0.1% in the placebo group vs. 0% in the LPR group, as detected by V123 with \( P = 0.01 \); 0.5% in the placebo group vs. 0.2% in the LPR group, as detected by V456 with \( P = 0.02 \)). Interestingly, in females, the relative abundance of bacteria of the Lachnospiraceae family, a dominant taxonomic group, was consistently reduced in the LPR group at week 12 (36.9% in the placebo group vs. 30.3% in the LPR group, as detected by V123 with \( P = 0.009 \); 32.9% in the placebo group vs. 24.5% in the LPR group, as detected by V456 with \( P = 0.001 \)) and week 24 (38.2% in the placebo group vs. 27.6% in the LPR group, as detected by V123 with \( P = 0.001 \); 32.6% in the placebo group vs. 24.5% in the LPR group, as detected by V456 with \( P = 0.03 \)). The results obtained for the relative abundance of bacteria of the Lachnospiraceae family with V123 are shown in Fig. 4. Differences in the abundance of members of the Lachnospiraceae family were essentially driven at the genus level by bacteria classified in the _Roseburia_ genus and unclassified in the Lachnospiraceae family, although none reached the statistical significance threshold (data not shown). The only other significant difference detected between the LPR-treated and placebo-treated females was a reduction in the abundance of bacteria of the _Subdoligranulum_ genus detected at week 12 (4.8% in the placebo group vs. 2.9% in the LPR group, as detected by V123 with \( P = 0.01 \); 4.1% in the placebo group vs. 2.5% in the LPR group, as detected by V456 with \( P = 0.02 \)). This taxonomic group belongs to the closely related Ruminococcaceae family.

**Faecal Lactobacillus rhamnosus CGMCC1.3724 detection**

Faecal LPR was quantified by real-time PCR using strain-specific primers and TaqMan probes. At week 12, the percentage of subjects with detectable LPR in the faeces increased to 90% in the treated group, whereas in the placebo group, only 10% of the subjects showed LPR-positive signals (Fig. 5; Fisher’s exact test \( P < 0.001 \)). A similar percentage of subjects with detectable faecal LPR were observed at week 24 (Fig. 5; Fisher’s exact test \( P < 0.001 \)). The faecal abundance of LPR in the LPR-positive subjects in the treated group was similar at weeks 12 and 24 (week 12: 7.7 (SE 1.1) \times 10^6\) genome equivalents/g faeces; week 24: 5.4 (SE 0.9) \times 10^6\) genome equivalents/g faeces). At week 12, the percentage of detectable faecal LPR was similar in males and females (90.9 and 90.0%, respectively; Fisher’s exact test \( P = 1 \)), whereas at week 24, it was slightly lower in males than in the females (77.8 and 85.7%, respectively; Fisher’s exact test \( P = 0.424 \)).

**Dropout rate**

As shown in Fig. 1, the dropout rate was less than 25%. The main reason given by the dropouts was the lack of time. There was one participant who was excluded because of the poor compliance to the treatment (more than three consecutive days without the treatment). No adverse events were reported as a dropout reason. There was no significant difference between the two groups for the dropout rate.
agreement with the findings of previous studies investigating
observed in the present study between men and women is in
abundance levels between the sexes. The small difference
effect. At baseline, only a single low-abundance taxo-
that the gut microbiota may be involved in the LPR-induced
results of the present study showing higher weight loss in

Fig. 5. Comparisons of the weighted UniFrac distances between samples (■) collected during each period (W0, baseline; W12, week 12; W24, week 24) and between paired samples collected from the same subjects (□) at the end of the weight-loss period (W12, week 12) and the end of the trial (W24, week 24). Values are means, with their standard errors represented by vertical bars.

Discussion

Obesity is a multifactorial problem that requires the consider-
ation of numerous relevant factors when designing a potential
successful intervention. Recent literature provides evidence
that gut microflora might be involved in the etiology of obesity.
In this regard, we conducted the present study to evaluate the
impact of a LPR formulation on body weight and fat
mass in obese men and women.

During the energy-restriction period, administration of the
LPR formulation did not significantly decrease the body
weight or fat mass of an obese population regrouping men
and women. However, at the end of the weight-maintenance
phase, the LPR group tended to lose more fat mass than the
placebo group. A subgroup analysis revealed that the
observed trend was mainly driven by a significant reduction in
fat mass in women. Analysis of the sex-specific results
revealed significantly higher body-weight and fat mass losses
promoted by the LPR treatment at the end of the energy-
restriction phase and after the weight-maintenance phase in
women but not in men. Measurements of the abundance
and prevalence of LPR in faeces of the placebo and LPR
groups indicated good treatment compliance and did not
reveal any significant difference between the sexes.

Our clinical experience indicates that men are generally
more prone to respond to a negative-energy balance interven-
tion than women, be it in response to an exercise-training
programme(38), a diet–exercise programme(39), or a session of
exercise and of mental work(40). This is concordant with the
results of the present study showing higher weight loss in
men in the placebo group than in the women. The fact that
the LPR supplementation abolished this difference suggests
that the gut microbiota may be involved in the LPR-induced
effect. At baseline, only a single low-abundance taxo-
nomic group (Prevotellaceae) showed significantly different
abundance levels between the sexes. The small difference
observed in the present study between men and women is in
agreement with the findings of previous studies investigating
sex-associated signatures, generally reporting only minor
and inconsistent differences(41–43). Consequently, the baseline
microbiota composition is unlikely to explain the sex-specific
responses to the LPR treatment. Interestingly, whereas the LPR
treatment did not induce any major change in the microbiota
composition in men, the abundance of bacteria of the
Lachnospiraceae family was substantially and significantly
reduced by the LPR treatment in women at both week 12
and week 24. The Lachnospiraceae family belongs to the
Firmicutes phylum, a taxonomic group that has previously
been reported to be positively associated with obesity(46,49,9,10).
However, associations between microbiota composition and
obesity show only limited consistency between independent
studies(44), making it difficult to identify specific bacterial
groups that could contribute to the obese phenotype. Both posi-
tive and negative associations have been reported between the
intestinal levels of Lachnospiraceae family members and obesity(45,46). Taken together, these observations suggest that
bacteria of the Lachnospiraceae family might play a role in
obesity and that the seeming contradictions may be due to
differences in hosts (human and mouse), conditions (age,
diet, etc.) and techniques used to measure the microbiota com-
position. Interestingly, alterations in the abundance of bacteria
of the Lachnospiraceae family (enrichment of an unknown
Lachnospiraceae family member and reduction in the abun-
dance of the Roseburia species) and an increased abundance of
an unknown bacterium closely related to the Subdoligranulum
genus have also been reported in association with type 2
diabetes in a human metagenomic study(12). Similar results
have been obtained in another type 2 diabetes human study
carried out using 16S profiling(47), suggesting a progressive
modification of the microbiota composition from obese individ-
uals losing weight on dietary restriction to obese individuals
with type 2 diabetes through healthy obese individuals. It is
worth noting that the taxonomic groups identified in the present
study are among the most important intestinal producers of
SCFA derived from carbohydrate fermentation(48). Among
other mechanisms, these compounds have been proposed as
mediators of the interaction between gut microbes and the
host in the regulation of energy metabolism(49,50).

In addition to its effect on weight and fat mass loss, the
LPR formulation reduced by about 25% circulating leptin
concentrations at the end of the weight-maintenance phase.
Statistical analysis correcting for fat mass loss between
baseline and week 24 revealed that circulating leptin concen-
trations were regulated independently of fat mass reduction.
These data suggest that LPR could lower plasma leptin
concentrations directly or through changes in the microbiota
composition or function. Interestingly, the relative abundance
of bacteria of the Lachnospiraceae family has been reported to
be positively associated with circulating leptin concentrations
in mice after weight loss(45). Reductions in plasma leptin
concentrations were preferentially observed in women who
had about 3-fold higher baseline leptin concentrations than
in men (Table 1), suggesting that LPR was more prone to
reduce leptin concentrations in elevated leptin concentra-
tion conditions. Since the SCFA stimulate leptin production in
adipocytes(51), the reduction in the abundance of SCFA
producers belonging to the Lachnospiraceae family and Subdoligranum genus observed in the LPR-treated women may explain the reduction in circulating leptin concentrations.

No significant changes in other physiological, metabolic and inflammatory markers of the metabolic syndrome were observed in the treated group. The absence of changes in the plasma metabolic and inflammatory markers may be explained by the fact that the inclusion and exclusion criteria used in the present study prevented the recruitment of subjects displaying an unhealthy metabolic profile. This does not exclude that LPR can improve the condition of obese individuals exhibiting the metabolic syndrome, but the present results suggest that these potential benefits are at least limited in metabolically healthy individuals.

It is well established that a major difficulty related to obesity management is the capacity to maintain body weight after significant weight loss. This is concordant with the findings of studies showing that body-weight and fat mass losses favour a greater-than-predicted decrease in energy expenditure\(^{(52,53)}\) and a significant increase in hunger feelings\(^{(54)}\). Thus, in a reduced obese state, it is essential that some lifestyle changes be made to compensate for the trend towards weight regain. In the present study, recommendations of healthy eating at the end of the weight-loss phase (phase 1) appeared to be successful in men in the placebo group as well as in the two groups of subjects who continued the LPR supplementation. In contrast, fat regain was observed in women in the placebo group during the weight-maintenance phase, suggesting that probiotics may help obese women to maintain healthy body weight.

It is important to mention that there was probably no independent prebiotic effect in the LPR group considering that 600 mg of daily dose of inulin and oligofructose (70:30, v/v) included in the LPR capsules are not sufficient to exert an effect on weight loss. In contrast, in a study, a daily dose of 16 g of inulin–oligofructose (50:50, v/v) in obese women led to changes in the gut microbiota composition that were of a magnitude similar to that observed in the present study, but of different orientation or in different taxonomic groups, and without a significant effect on body weight\(^{(55)}\). Even if a slight impact on gut microbiota composition cannot be excluded, it is unlikely that weight loss observed in the LPR group can be attributed to the prebiotic mix contained in the capsules. Fibres were used to increase probiotic survival in the gastric (low pH) and duodenal (presence of bile salts) conditions, thereby supporting probiotic functionalities.

In summary, the present study demonstrates that LPR supplementation can accentuate body-weight loss in women submitted to energy restriction. This effect persisted in the subsequent maintenance phase when energy restriction was not imposed further. Thus, LPR supplementation seems to help obese women to maintain healthy body weight. Further research is needed to provide mechanistic explanations of this effect on energy balance.

Acknowledgements

The authors thank Lucie Brunelle, Marlene Gagnon-Sweeney and Sabrina Turgeon for their contribution to data collection, Stéphane Duboux and Alain Frachebout for their contribution to probiotic formulation preparation, and the nurse team.

The present study was sponsored by The Nestlé Research Center (Lausanne, Switzerland). The funder contributed to the study design and carried out the analysis of the faecal samples and some blood samples. In addition, some members of The Nestlé Research Center contributed to the preparation of the manuscript.

The authors’ contributions are as follows: M. S. wrote the manuscript; A. T., C. D., V. D., S. E.-A., M. L., E. R., C. N.-B., B. B., L. P., C. A.-Z., P. L., G. C., E. S., A. M. and J. D. prepared the manuscript; C. N.-B. conducted the bioinformatics analysis; S. E.-A. and M. L. conducted the statistical analyses; C. A.-Z., G. C., A. M. and E. S. conducted the blood marker analyses; P. L. performed faecal probiotic quantification.

None of the authors has any conflicts of interest to declare.

References


